Frovatriptan - Medication and Pregnancy KB

Frovatriptan

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Spielmann (Control mainly exposed other treatments, sick) 2017	Germany 1999 - 2014 prospective cohort	German Embryotox system	Pregnant women with Frovatriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Pregnant women suffering from migraine disorder but not taking triptans between their last menstrual period and delivery.	during pregnancy (anytime or not specified)	19 / 475	The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.
	Germany 1999 - 2014 prospective cohort	German Embryotox system	All data are recorded using structured questionnaires via phone interview and/or as a written form.		during pregnancy (anytime or not specified)	19 / 475
Spielmann (Control unexposed, disease free) 2017	Germany 1999 - 2014 prospective cohort	German Embryotox system	Pregnant women with Frovatriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, disease free Pregnant women without migraine disorder who were neither exposed to triptans nor to one of the following established teratogens or fetotoxicant.	during pregnancy (anytime or not specified)	19 / 1733	The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.
Spielmann (Control unexposed, disease free) 2017	Germany 1999 - 2014 prospective cohort	German Embryotox system	All data are recorded using structured questionnaires via phone interview and/or as a written form.		during pregnancy (anytime or not specified)	19 / 1733

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol